Commentary: The Long History of Vitamin C: From Prevention of the Common Cold to Potential Aid in the Treatment of COVID-19Immunology Published on 2021-04-012022-11-01 Journal: Frontiers in Immunology [Category] Coronavirus, MERS, SARS, [키워드] AID ascorbic acid Cold common common cold coronavirus COVID-19 history immune system Long Pneumonia Potential prevention Respiratory tract infections rhinovirus Vitamin [DOI] 10.3389/fimmu.2021.659001 PMC 바로가기 [Article Type] Immunology
COVID-Well Study: Qualitative Evaluation of Supported Wellbeing Centres and Psychological First Aid for Healthcare Workers during the COVID-19 PandemicArticle Published on 2021-03-312022-10-29 Journal: International Journal of Environmental Research an [Category] COVID-19, SARS, [키워드] addressed AID analysed approach benefit Care COVID-19 COVID-19 pandemic Critical healthcare hospital Impact individuals Intervention interview National Health Service NHS pandemic peer-to-peer support provided Psychological psychological Impact psychological support Psychological wellbeing Qualitative recorded Support thematic analysis training transcribed Volunteer worker workforce [DOI] 10.3390/ijerph18073626 PMC 바로가기 [Article Type] Article
Generation of Plasmodium yoelii malaria parasite for conditional degradation of proteinsarticle Published on 2021-01-312024-09-01 Journal: Molecular and Biochemical Parasitology [Category] 말라리아, [키워드] AID malaria parasite Plasmodium yoelii Protein degradation [Article Type] article
The Long History of Vitamin C: From Prevention of the Common Cold to Potential Aid in the Treatment of COVID-19Immunology Published on 2020-10-282022-11-01 Journal: Frontiers in Immunology [Category] COVID-19, MERS, SARS, [키워드] Affect AID Athletes available data boost immunity category Cold common Concentration conditions COVID-19 Critical diabetics Effect frail elderly subjects General population Health high risk High-dose history hospitalized patients immune function immune response immune system Infection infections Inflammation Long modulate non-communicable diseases obese physiological plasma Pneumonia positive Potential prevention recommendation reduce Respiratory disease respiratory infection risk SARS-CoV2 infection significantly subgroup subject Support susceptibility Treatment treatment for COVID-19 viral infections Vitamin Vitamin C vitamin C supplementation [DOI] 10.3389/fimmu.2020.574029 PMC 바로가기 [Article Type] Immunology
Misalignment between coronavirus financial aid and public health policies: negative incentives for outpatient clinics in the United StatesViewpoint Published on 2020-09-252022-10-30 Journal: Journal of public health policy [Category] Coronavirus, SARS, [키워드] Act AID Clinical practice clinics coronavirus COVID-19 COVID-19 infection downstream Effect employment evaluated implication increased risk maintain Measures patients Policy Program protection public health relief SARS-CoV2 security Telemedicine the United State United State [DOI] 10.1057/s41271-020-00256-9 PMC 바로가기 [Article Type] Viewpoint
Mainstream reintegration of COVID-19 survivors and its implications for mental health care in AfricaEssay Published on 2020-08-282022-10-28 Journal: The Pan African Medical Journal [Category] COVID-19, MERS, SARS, [키워드] AID anxiety disorders Care Community country COVID-19 Depression disorders emotional emotional distress facilitate health worker healthcare help implication Infectious disease inherent mainstream mental health National Novel coronavirus Obsessive-compulsive disorder offer outbreak pandemic Patient promote protocol Psychological Psychological distress Psychosocial distress public health threat required Support survivor Survivors virus [DOI] 10.11604/pamj.2020.36.366.25115 PMC 바로가기 [Article Type] Essay
Could Ergothioneine Aid in the Treatment of Coronavirus Patients?Review Published on 2020-07-072022-10-28 Journal: The Cochrane database of systematic reviews [Category] COVID-19, [키워드] acute respiratory distress AID Amino acid antioxidant cause conditions coronavirus COVID-19 COVID-19 patient Critical cytokine develop dysregulation Endothelial dysfunction Ergothioneine Evidence excessive inflammation exhibited Free radicals gastrointestinal tract Health in vitro in vivo models Infectious disease Inflammation Ischemia kidneys liver Liver fibrosis lung Lungs mitigate modulate Mortality multiorgan failure NETs neuronal Numerous pandemic pathology Prevent PROTECT reduce reperfusion injury SARS SARS-CoV-2 severity Support syndrome therapeutic Treatment unique [DOI] 10.3390/antiox9070595 PMC 바로가기 [Article Type] Review
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial후보 중동 호흡기 증후군 코로나바이러스 바이러스 매개 백신의 안전성 및 면역원성: 용량 증량, 공개, 비무작위, 비통제, 1상 시험Article Published on 2020-07-012022-08-13 Journal: The Lancet. Infectious Diseases [Category] 임상, [키워드] absence adverse event AID All participant All participants antibody Antigen Arabian Peninsula assigned baseline cellular cellular and humoral immunogenicity cellular response ChAdOx1 ChAdOx1 MERS clinical clinical development clinical trial coronavirus Department described dose dose-escalation doses effective elicit ELISA enzyme enzyme-linked immunospot expressing finding FIVE Follow-up follow-up period full-length full-length spike surface glycoprotein funding healthy hepatitis B hepatitis B surface antigen hepatitis C hepatitis C antibodies hepatitis C antibody High-dose high-dose group HIV antibodies humans humoral humoral immunogenicity IgG immunogenicity ImmunoSpot Infection interferon interferon-γ-linked enzyme-linked immunospot intermediate-dose group Intervention Intramuscular injection low-dose Medicine MERS MERS-CoV MERS-CoV spike antigen Middle East Middle East respiratory syndrome Coronavirus Mild mild in severity moderate neutralisation neutralisation assay Neutralising Antibodies nine Occurrence Open-label Oxford participant Phase 1 phase 1 trial pre-vaccination test pre-vaccination tests pregnancy test progression proportion Pseudotyped virus public health Registered Relative risk reported resolved respiratory respiratory syndrome coronavirus response risk Safe Safety Saudi Arabia Serious Adverse Event Serious Adverse Events severe adverse event significant increase significantly higher simian adenovirus-vectored vaccine single dose Support surface antigen Surface glycoprotein T-cell tested Tolerability trials tropical medicine urinary pregnancy test vaccination vectored vaccine Viral viral particle Viral particles virus neutralising assay virus neutralising assays was done women [DOI] 10.1016/S1473-3099(20)30160-2 PMC 바로가기 [Article Type] Article
Protecting the Prehospital Professional First Aid Teams from Airborne Viral Particles in the Case of Out-of-Hospital Pediatric Cardiac Arrest during the COVID-19 PandemicLetter to the Editor Published on 2020-05-122022-10-29 Journal: Prehospital and Disaster Medicine [Category] Coronavirus, MERS, SARS, [키워드] AID arrest cardiac COVID-19 Particle prehospital professional Protecting team [DOI] 10.1017/S1049023X2000062X PMC 바로가기 [Article Type] Letter to the Editor
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trialHIV의 2차 치료를 위한 로피나비르 + 뉴클레오시드 역전사효소 억제제, 로피나비르 + 랄테그라비르 또는 로피나비르 단독요법(EARNEST): 무작위 대조 시험의 144주 추적 결과Article Published on 2018-01-012022-09-06 Journal: The Lancet. Infectious Diseases [Category] Communicable Disease, [키워드] adverse event African AID analysed Analysis Antiretroviral therapy ART assigned best clinical Combination combination therapy completion computer-generated cooperation country criteria Developing development Efficacy eligibility European event finding FIVE Follow-up funding GRADE grade 3 group HIV-infected people inferiority inhibitor inhibitors intervention group ISRCTN Kenya less limit Lopinavir Medical Research Council Modification monotherapy no difference non-inferiority non-inferiority margin nucleoside offer offered outcome participant partnership Patient per day primary analysis Primary outcome protease Protease inhibitor raltegravir randomisation randomised controlled trial Randomly receive recent regimen regimens Registered Ritonavir screened sequence Serious Adverse Events Swedish Treatment treatment of HIV Trial two-sided α Uganda Viral Viral load viral loads Virological WHO WHO criteria WHO guideline Zimbabwe [DOI] 10.1016/S1473-3099(17)30630-8 PMC 바로가기 [Article Type] Article